RSS

Orchard Therapeutics

Orchard Therapeutics, a commercial stage company, has been granted a Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for its gene therapy candidate, OTL-200, for the treatment of patients with MLD more

News

Orchard Therapeutics, a commercial and clinical-stage company, has opened a new US office located in Boston’s Seaport District, building upon the company’s footprint in London as well as Foster City and Menlo Park, California. more

News

A strategic agreement has been signed by GlaxoSmithKline (GSK) and Orchard Therapeutics, involving the transfer of GSK’s portfolio of approved and investigational rare disease gene therapies to Orchard. more

News

Clinical-stage biotechnology company, Orchard Therapeutics, has opened a second facility in San Francisco, California, expanding its technical operations. more

News

Orchard Therapeutics, a clinical-stage biotechnology company, has acquired an exclusive licence to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B (or MPS-IIIB) from The University of Manchester. more

News